Tech Company Financing Transactions

Intarcia Therapeutics Funding Round

On 3/19/2007, Intarcia Therapeutics received $50 million in Series B financing from New Leaf Venture Partners, Alta Partners and GGV Capital.

Transaction Overview

Announced On
3/19/2007
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The Company will use the proceeds to fund ongoing clinical development of its Omega DUROS® therapy for chronic hepatitis C, and to advance its diabetes development program into phase 1.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Email Address
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Intarcia Therapeutics LinkedIn Company Profile
Social Media
Intarcia Therapeutics Company Twitter Account
Company News
Intarcia Therapeutics News
Facebook
Intarcia Therapeutics on Facebook
YouTube
Intarcia Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
  Kurt Graves LinkedIn Profile  Kurt Graves Twitter Account  Kurt Graves News  Kurt Graves on Facebook
Chief Scientific Officer
Andrew Young
  Andrew Young LinkedIn Profile  Andrew Young Twitter Account  Andrew Young News  Andrew Young on Facebook
VP - Client Services
Jay Smith
  Jay Smith LinkedIn Profile  Jay Smith Twitter Account  Jay Smith News  Jay Smith on Facebook
VP - General Counsel
Raymond Keane
  Raymond Keane LinkedIn Profile  Raymond Keane Twitter Account  Raymond Keane News  Raymond Keane on Facebook
VP - Human Resources
James Brady
  James Brady LinkedIn Profile  James Brady Twitter Account  James Brady News  James Brady on Facebook
VP - Manufacturing
Thomas Alessi
  Thomas Alessi LinkedIn Profile  Thomas Alessi Twitter Account  Thomas Alessi News  Thomas Alessi on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/19/2007: Theraclone Sciences venture capital transaction
Next: 3/19/2007: NeuroPure venture capital transaction

 

Share this article

 


News on VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary